In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2012-02-18 00:07 | 2012-02-16 | MYGN | MYRIAD GENETICS INC | MELDRUM PETER D | Director, Officer | OPT+S | $23.78 | 30,296 | $720,415 | 180,901 |
| 2012-02-10 01:06 | 2012-02-07 | MYGN | MYRIAD GENETICS INC | MARSH RICHARD M | Officer | OPT+S | $24.02 | 12,686 | $304,749 | 0 |
| 2012-02-10 01:11 | 2012-02-07 | MYGN | MYRIAD GENETICS INC | MELDRUM PETER D | Director, Officer | OPT+S | $24.00 | 6,500 | $156,000 | 180,921 |
| 2012-02-08 01:20 | 2012-02-03 | MYGN | MYRIAD GENETICS INC | Evans James S | Officer | OPT+S | $23.98 | 8,800 | $211,028 | 45,598 |
| 2012-02-08 01:23 | 2012-02-03 | MYGN | MYRIAD GENETICS INC | MELDRUM PETER D | Director, Officer | OPT+S | $23.97 | 53,222 | $1,275,566 | 180,921 |
| 2012-02-03 00:12 | 2012-02-01 | MYGN | MYRIAD GENETICS INC | LANCHBURY JERRY S | Officer | OPT+S | $24.05 | 21,804 | $524,338 | 22,735 |
| 2012-02-03 00:20 | 2012-01-31 | MYGN | MYRIAD GENETICS INC | MELDRUM PETER D | Director, Officer | OPT+S | $23.95 | 30,200 | $723,233 | 180,921 |
| 2012-02-01 19:37 | 2012-01-31 | IDEXX | IDEXX LABORATORIES INC /DE | NAQUI ALI | Officer | SELL | $84.64 | 3,056 | $258,660 | 16,786 |
| 2012-01-28 00:56 | 2012-01-25 | MYGN | MYRIAD GENETICS INC | MELDRUM PETER D | Director, Officer | OPT+S | $23.04 | 15,000 | $345,638 | 180,921 |
| 2012-01-19 18:41 | 2012-01-17 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director, Officer | OPT+S | $82.81 | 15,320 | $1,268,634 | 327,791 |
| 2012-01-06 01:04 | 2012-01-04 | NEOG | NEOGEN CORP | PARNELL JACK C | Director | SELL | $31.25 | 3,000 | $93,747 | 11,585 |
| 2012-01-05 18:44 | 2012-01-04 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director, Officer | OPT+S | $78.54 | 15,000 | $1,178,114 | 322,791 |
| 2012-01-03 21:06 | 2011-12-27 | NEOG | NEOGEN CORP | YEUTTER CLAYTON K | Director | BUY | $30.92 | 3,700 | $114,404 | 7,310 |
| 2011-12-30 18:42 | 2011-12-27 | NEOG | NEOGEN CORP | Quinlan Steven J. | Officer | BUY | $31.12 | 3,214 | $100,005 | 3,361 |
| 2011-12-28 19:03 | 2011-12-23 | NEOG | NEOGEN CORP | FISCHER A. CHARLES | Director | BUY | $30.91 | 1,000 | $30,910 | 2,000 |
| 2011-12-20 22:04 | 2011-12-19 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director, Officer | OPT+S | $73.64 | 15,000 | $1,104,537 | 317,697 |
| 2011-12-20 22:03 | 2011-12-16 | IDXX | IDEXX LABORATORIES INC /DE | MURRAY ROBERT J | Director | BUY | $74.54 | 6,500 | $484,520 | 19,746 |
| 2011-12-09 17:41 | 2011-12-08 | ICCC | IMMUCELL CORP /DE/ | CRABB JOSEPH H | Director, Officer | BUY | $3.20 | 1,000 | $3,200 | 114,111 |
| 2011-12-01 16:26 | 2011-11-30 | IDXX | IDEXX LABORATORIES INC /DE | DEADY CONAN R | Officer | SELL | $74.88 | 3,000 | $224,651 | 15,562 |
| 2011-11-29 21:58 | 2011-11-28 | IDXX | IDEXX LABORATORIES INC /DE | HENDERSON REBECCA M | Director | OPT+S | $71.43 | 5,000 | $357,136 | 8,348 |
| 2011-11-23 22:23 | 2011-11-22 | NEOG | NEOGEN CORP | HERBERT JAMES L | Director, Officer | SELL | $35.59 | 3,424 | $121,860 | 820,629 |
| 2011-11-22 16:45 | 2011-11-18 | NEOG | NEOGEN CORP | HERBERT JAMES L | Director, Officer | SELL | $36.74 | 7,000 | $257,180 | 824,053 |
| 2011-11-18 21:55 | 2011-11-17 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director, Officer | OPT+S | $74.70 | 15,000 | $1,120,437 | 312,697 |
| 2011-11-18 18:23 | 2011-11-17 | NEOG | NEOGEN CORP | HERBERT JAMES L | Director, Officer | OPT+S | $38.26 | 2,280 | $87,233 | 828,773 |
| 2011-11-17 22:23 | 2011-11-15 | VRML | Aspira Women's Health Inc. | HUEBNER BRUCE A | Director | BUY | $1.70 | 30,932 | $52,529 | 40,427 |
| 2011-11-17 01:14 | 2011-11-16 | VRML | Aspira Women's Health Inc. | Creech William B. | Officer | BUY | $1.75 | 3,000 | $5,248 | 29,434 |
| 2011-11-16 01:14 | 2011-11-15 | VRML | Aspira Women's Health Inc. | Schoen Eric | Officer | BUY | $1.18 | 19,525 | $23,043 | 21,525 |
| 2011-11-11 00:09 | 2011-11-08 | NEOG | NEOGEN CORP | HERBERT JAMES L | Director, Officer | SELL | $38.86 | 3,000 | $116,580 | 826,061 |
| 2011-11-04 18:57 | 2011-11-03 | NEOG | NEOGEN CORP | BRADLEY EDWARD | Officer | OPT+S | $38.71 | 5,850 | $226,454 | 109,521 |
| 2011-11-04 16:37 | 2011-11-02 | NEOG | NEOGEN CORP | HERBERT JAMES L | Director, Officer | OPT+S | $37.71 | 13,470 | $507,954 | 827,333 |
| 2011-11-02 21:50 | 2011-11-01 | VRML | Aspira Women's Health Inc. | Creech William B. | Officer | BUY | $1.98 | 957 | $1,895 | 26,434 |
| 2011-11-03 00:05 | 2011-10-31 | NEOG | NEOGEN CORP | BOHANNON LON M | Director, Officer | OPT+S | $38.52 | 9,898 | $381,311 | 293,446 |
| 2011-10-14 00:30 | 2011-10-11 | NEOG | NEOGEN CORP | YEUTTER CLAYTON K | Director | BUY | $34.87 | 145 | $5,056 | 3,610 |
| 2011-10-06 20:23 | 2011-10-04 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director, Officer | OPT+S | $65.24 | 30,000 | $1,957,281 | 307,697 |
| 2011-10-04 00:50 | 2011-09-29 | NEOG | NEOGEN CORP | Quinlan Steven J. | Officer | SELL | $34.38 | 147 | $5,066 | 647 |
| 2011-10-04 00:52 | 2011-10-03 | VRML | Aspira Women's Health Inc. | Creech William B. | Officer | BUY | $2.81 | 767 | $2,155 | 25,447 |
| 2011-10-04 00:15 | 2011-09-30 | NEOG | NEOGEN CORP | REED THOMAS H | Director | SELL | $34.60 | 1,000 | $34,600 | 3,668 |
| 2011-09-30 20:11 | 2011-09-29 | NEOG | NEOGEN CORP | REED THOMAS H | Director | SELL | $34.11 | 1,000 | $34,110 | 2,668 |
| 2011-09-15 21:10 | 2011-09-15 | VRML | Aspira Women's Health Inc. | Kohli Ashish | Officer | BUY | $3.01 | 2,000 | $6,016 | 13,500 |
| 2011-09-08 23:47 | 2011-09-07 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director, Officer | OPT+S | $76.03 | 15,000 | $1,140,479 | 297,618 |
| 2011-09-02 00:08 | 2011-09-01 | VRML | Aspira Women's Health Inc. | Creech William B. | Officer | BUY | $2.81 | 717 | $2,015 | 24,680 |
| 2011-08-25 00:49 | 2011-08-23 | NEOG | NEOGEN CORP | BOEHM WILLIAM T | Director | BUY | $35.06 | 500 | $17,530 | 1,000 |
| 2011-08-23 15:39 | 2011-08-19 | ICCC | IMMUCELL CORP /DE/ | Tomsche David Scott | Director | BUY | $5.80 | 15,000 | $87,000 | 52,668 |
| 2011-08-23 16:01 | 2011-08-19 | IDXX | IDEXX LABORATORIES INC /DE | DEADY CONAN R | Officer | OPT+S | $74.09 | 9,984 | $739,734 | 19,347 |
| 2011-08-17 01:35 | 2011-08-04 | NEOG | NEOGEN CORP | CROWDER RICHARD T | Director | BUY | $38.11 | 500 | $19,055 | 1,000 |
| 2011-08-17 02:00 | 2011-08-12 | NEOG | NEOGEN CORP | YEUTTER CLAYTON K | Director | BUY | $36.47 | 1,000 | $36,465 | 4,465 |
| 2011-08-16 20:35 | 2011-08-12 | IDXX | IDEXX LABORATORIES INC /DE | RAINES MERILEE | Officer | OPT+S | $76.52 | 12,200 | $933,511 | 183,094 |
| 2011-08-12 23:09 | 2011-08-12 | VRML | Aspira Women's Health Inc. | Creech William B. | Officer | BUY | $2.75 | 1,000 | $2,750 | 23,963 |
| 2011-08-11 20:42 | 2011-08-11 | CLDX | Celldex Therapeutics, Inc. | KELER TIBOR | Officer | BUY | $2.50 | 5,000 | $12,520 | 15,868 |
| 2011-08-10 16:54 | 2011-08-09 | CLDX | Celldex Therapeutics, Inc. | Marucci Anthony S | Director, Officer | BUY | $2.41 | 15,000 | $36,161 | 5,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.